AbbVie: CHMP Recommends Approvals of Rinvoq for Psoriatic Arthritis, Ankylosing Spondylitis
December 11 2020 - 8:24AM
Dow Jones News
By Michael Dabaie
AbbVie Inc. said Friday the European Medicines Agency's
Committee for Medicinal Products for Human Use, or CHMP,
recommended the approval of Rinvoq for active psoriatic arthritis
and active ankylosing spondylitis.
The positive opinions are based on results from three pivotal
clinical studies in which Rinvoq demonstrated efficacy across
multiple measures of disease activity, AbbVie said.
The CHMP positive opinion is a scientific recommendation for
marketing authorization to the European Commission, the company
said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 11, 2020 08:09 ET (13:09 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024
